Westlake Vita Completes Tens of Millions RMB Pre-A+ Financing to Advance R&D of Innovative Diagnostic Technologies

VCBeat has learned that Westlake Vitae recently announced the completion of a Pre-A+ financing round, raising tens of millions of yuan in additional capital. The round was led by Meihong Investment, with participation from Zhejiang Tenghua Asset Management Co., Ltd., Hangzhou Xihu Kechuang Equity Investment Co., Ltd., and other institutional investors. The funds raised will support Westlake Vitae’s rapid development in new product R&D, business expansion, and channel promotion.

Westlake Vitae (Hangzhou) Diagnostics Technology Co., Ltd. is a comprehensive medical platform dedicated to the research and translation of innovative diagnostic technologies based on serology, cytology, and genetics. The company focuses on early screening, prevention, diagnosis, and treatment of clinical diseases, aiming to build integrated solutions for precise diagnosis and supplementation. Currently, Westlake Vitae has taken the lead in realizing the research, development, and translation of technologies for detecting erythrocyte metabolic function of B-complex vitamins. The company will continue to advance the development of multiple innovative products, including multi-gene innovative diagnostic kits for congenital heart disease and diagnostic and therapeutic solutions for heart failure.

Westlake Vitae was established in May 2021 by Dr. Shi Hongjun of Westlake University, with its headquarters located in Hangzhou. Its business covers medical testing services, precision laboratory construction, scientific research services, and the research, development, and manufacturing of IVD diagnostic reagents. The company focuses on providing clinical services such as personalized diagnosis and medication guidance for reproductive health, birth defects, cardiovascular and cerebrovascular diseases, and metabolic disorders. Benefiting from rapid growth and talent acquisition over the past two years, Westlake Vitae has built a strong R&D and operational team, with more than 50% of its senior R&D and marketing professionals holding master’s or doctoral degrees, thereby strengthening its capabilities in technological innovation and market expansion.

Currently, Westlake Vitae’s proprietary diagnostic technologies have been deployed in clinical testing and research collaborations with hundreds of Grade 3A hospitals across China, earning high recognition from experts and the industry. Westlake Vitae remains committed to a clinical problem-oriented approach, integrating biological research with novel diagnostic technologies, and bridging basic theoretical research with clinical translation. The company strives to establish a seamless continuum spanning from disease pathogenesis to in vitro diagnostics and ultimately to precision medication guidance.

Meihong Investment is a private equity investment firm established by former shareholders and senior executives of Meinian Onehealth (SZ: 002044) in collaboration with industry experts, and has attracted a large pool of top-tier investment talent. Meihong Investment focuses on equity investments in growth-stage non-listed companies across the upstream, midstream, and downstream sectors closely related to the healthcare and wellness industry. It leverages its extensive investment experience and industrial resources in the medical services sector to empower its portfolio companies. Adhering to the philosophy of “Health for a Future: Capturing the Deterministic Value in China’s Health Investment Trends,” Meihong Investment is committed to investing in innovative healthcare and building an innovative ecosystem for medical services, serving as an incubation platform that helps Chinese healthcare startups set sail.